Prostate cancer
Prostate cancer The food and Drug Administration scientists say an Amgen drug slowed the spread of cancer to the bones in men with hard disk of treating prostate cancer, although the drug was not applied to life and led to significant side effects.
Prostate cancer The Food and Drug Administration asked a panel of external experts on Wednesday if the benefits of the Amgen Xgeva outweigh their risks, including bone disease in about 5 percent of patients taking the drug. The Agency had published its review of Monday morning online drug prior to the meeting.
Prostate cancer Xgeva is already approved to prevent fractures in the cancerous bones and osteoporosis, in a different formulation called Prolia.
Now Amgen has asked the FDA to approve IDUs as a preventive measure for men with prostate cancer recurring that is at high risk of spread to the bone. Men should also have attempted and failed treatment with hormonal therapy.
Prostate cancer
A study of 1,432 patient by Amgen showed that the drug reduced the spread of cancer to the bones 4.2 months compared with patients receiving placebo. While this delay was statistically significant, FDA reviewers questioned whether it is "a proper measure of clinical benefit" for patients with prostate cancer.
Review of the FDA said that the drug did not increase overall survival, with patients in drug groups and placebo live about the same amount of time.Prostate
Read more ...
Source: http://aslam84099.typepad.com/blog/2012/02/prostate-cancer-1.html
jeff garcia jeff garcia big east jesse james pearl harbor day discovery channel lea michele
No comments:
Post a Comment